Nonsegmental Vitiligo clinical trials

Explore recruiting nonsegmental vitiligo clinical trials.

Recruiting nonsegmental vitiligo studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Nonsegmental Vitiligo trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

B7981080 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO

Germany, Italy, Bulgaria, Slovakia, Poland, Hungary +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

Denmark, Hungary, Germany, Austria, Bulgaria, Portugal +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

B7981040 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO

Bulgaria, Spain, Germany, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.

Poland, Italy, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo

Netherlands, Germany, Poland, Spain, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

Germany, Spain, Netherlands, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Nonsegmental Vitiligo trials by city

Nonsegmental Vitiligo in Toronto Nonsegmental Vitiligo in Vancouver Nonsegmental Vitiligo in Montreal Nonsegmental Vitiligo in Calgary Nonsegmental Vitiligo in Edmonton Nonsegmental Vitiligo in Ottawa Nonsegmental Vitiligo in Winnipeg Nonsegmental Vitiligo in Quebec City Nonsegmental Vitiligo in Hamilton Nonsegmental Vitiligo in Kitchener Nonsegmental Vitiligo in London Nonsegmental Vitiligo in Halifax Nonsegmental Vitiligo in New York Nonsegmental Vitiligo in Los Angeles Nonsegmental Vitiligo in Chicago Nonsegmental Vitiligo in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease